公开(公告)号：WO2019149628A1

公开(公告)日：2019-08-08

申请号：PCT/EP2019/051839

申请日：2019-01-25

Applicant: OMYA INTERNATIONAL AG

Inventor： BUDDE, Tanja ,  SHARMA, Lalit

IPC: A61K9/00 ,  A61K33/10 ,  A23L33/16

CPC classification number: A61K9/0053 ,  A23L33/16 ,  A61K33/10 ,  A61K45/06 ,  A61P3/02 ,  A61K2300/00

Abstract: The present invention relates to a dosage form comprising functionalized calcium carbonate serving as active ingredient. The invention further relates to the use of the dosage form as nutritional supplement or as a medicament and to the use of functionalized calcium carbonate as active ingredient, preferably in the field of calcium fortification and in the treatment of calcium deficiency.

公开(公告)号：WO2019055597A1

公开(公告)日：2019-03-21

申请号：PCT/US2018/050804

申请日：2018-09-13

Applicant: NATIONAL TUBEROUS SCLEROSIS ASSOCIATION, INC.

Inventor： BRUNNER, Daniela

IPC: A61K31/138 ,  A61K31/352 ,  A61K31/436

CPC classification number: C07K16/2896 ,  A01K67/027 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0306 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/48 ,  A61K31/00 ,  A61K31/436 ,  A61K38/162 ,  A61K38/164 ,  A61K45/06 ,  A61K2039/54 ,  A61K2039/545 ,  A61P35/00 ,  C07K14/47 ,  C07K2317/76 ,  C12N2800/30 ,  C12Q1/00 ,  G01N33/6893 ,  G01N2333/705 ,  A61K2300/00

Abstract: The treatment or prophylaxis of Tuberous Sclerosis Complex ("TSC") and conditions associated with TSC is disclosed. Treatments involve the administration of one or more TLR4 inhibitors to patients with TSC. Such administration may also treat or forestall conditions associated with TSC, including epilepsy and lymphangioleiomyomatosis.

公开(公告)号：WO2019050903A1

公开(公告)日：2019-03-14

申请号：PCT/US2018/049482

申请日：2018-09-05

Applicant: ENTERIN LABORATORIES, INC.

Inventor： BARBUT, Denise ,  ZASLOFF, Michael

IPC: A61K31/575 ,  A61P25/20

CPC classification number: A61K31/575 ,  A61K9/0043 ,  A61K9/0053 ,  A61K35/60 ,  A61P43/00

Abstract: This invention relates to methods of treating or preventing a sleep disorder, sleep disturbance, or related symptom in a subject with aminosterols or pharmaceutically acceptable salts or derivatives thereof. In particular, the disclosed methods generally comprise administering an aminosterol to a subject in need, thereby stimulating an aminosterol-induced CNS response to treat and/or prevent a sleep disorder, sleep disturbance, or related symptom.

公开(公告)号：WO2018220428A1

公开(公告)日：2018-12-06

申请号：PCT/IB2017/053243

申请日：2017-06-01

Applicant: MORINGO ORGANICS INC

Inventor： VIEIRA, Karen

IPC: A61K36/9066 ,  A61K35/74 ,  A61K36/185 ,  A61K36/47 ,  A61K36/48 ,  A61K36/53 ,  A61K36/67 ,  A61P39/06 ,  A61P29/00

CPC classification number: A61K36/31 ,  A61K9/0053 ,  A61K9/48 ,  A61K31/4525 ,  A61K35/04 ,  A61K35/74 ,  A61K35/748 ,  A61K36/185 ,  A61K36/47 ,  A61K36/48 ,  A61K36/53 ,  A61K36/61 ,  A61K36/67 ,  A61K36/9066 ,  A61K2300/00 ,  A61P3/06 ,  A61P3/10 ,  A61P39/06

Abstract: The main objective of the present invention is to develop an herbal formulation with high polyphenol concentrations. A therapeutic effect of ingredients in herbal composition with Antioxidants, Anti-inflammatories, Anti Viral & Anti Microbial properties to reduce Oxidative Stress, Inflammation, Viral and Microbial Infections. The herbal composition promotes management of diabetes, regulation of cholesterol, also immune system processes that helps to fight against viral and bacterial infections, colds, or the flu, skin ailments such as Psoriasis & eczema. Herbal Composition comprises synergistic combination of Moringa Oleifera Leaf Powder, Spirulina & Aqueous extracts of Oregano Vulgare Leaf Extract, Shilajit extract, Rosemary Leaf extract, Pomegranate Fruit Preel extract, Amla fruit extract, Fenugreek Seed Extract, Curcumin Extract, Piperine extract. Therefore, the chosen herbal blend provides the body with all of the vitamins, minerals, and nutrients it needs to continuously boost health.

公开(公告)号：WO2018220232A1

公开(公告)日：2018-12-06

申请号：PCT/EP2018/064656

申请日：2018-06-04

Applicant: UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Inventor： GIULIANO, François ,  DENYS, Pierre

IPC: A61K38/48 ,  A61K45/06 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5575 ,  G06F17/00 ,  G07F17/00

CPC classification number: A61K31/4985 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0034 ,  A61K9/0053 ,  A61K31/506 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5575 ,  A61K38/4893 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention is directed to a pharmaceutical combination product comprising botulinum toxin and atleast one proerectile agent for simultaneous, sequential or separate use in the treatment of erectile dysfunction.

公开(公告)号：WO2018195421A1

公开(公告)日：2018-10-25

申请号：PCT/US2018/028565

申请日：2018-04-20

Applicant: VANITALLIE, Theodore B.

Inventor： VANITALLIE, Theodore B.

IPC: A61K31/22 ,  A61P37/08

CPC classification number: A61K31/381 ,  A61K9/0053 ,  A61K31/045 ,  A61K31/12 ,  A61K31/121 ,  A61K31/19 ,  A61K31/22 ,  A61P37/08

Abstract: A nutritional agent that orally delivers a therapeutically effective amount of a ketone body selected from the group consisting of D-β-hydroxybutyrate (D-βOHB), acetoacetate (AcAc), acetone and any of their isoforms, in a carrier vehicle, to prevent and treat hypersensitivity and allergic disorders.

公开(公告)号：WO2018191579A1

公开(公告)日：2018-10-18

申请号：PCT/US2018/027418

申请日：2018-04-13

Applicant: CONTRAVIR PHARMACEUTICALS, INC.

Inventor： FOSTER, Robert Thomas ,  TREPANIER, Daniel Joseph ,  URE, Daren Raymond

IPC: A61K45/06 ,  A61K38/13 ,  C07K7/64 ,  A61P31/18

CPC classification number: A61K31/7115 ,  A61K9/0053 ,  A61K31/52 ,  A61K31/675 ,  A61K31/706 ,  A61K38/13 ,  A61K45/06 ,  A61K2300/00 ,  A61P31/18 ,  A61P31/20 ,  C07K7/645

Abstract: The present application relates to a method of treating and/or preventing a HBV disease or HIV disease or modulating HBV or HIV replication, comprising administering to a subject in need thereof a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with a nucleoside analog reverse transcriptase inhibitor or a nucleotide analog reverse transcriptase inhibitor.

公开(公告)号：WO2018170420A1

公开(公告)日：2018-09-20

申请号：PCT/US2018/022902

申请日：2018-03-16

Applicant: NORTHWESTERN UNIVERSITY

Inventor： MURPHY, Stephen, F. ,  THUMBIKAT, Praveen ,  SCHAEFFER, Anthony

IPC: A61K31/7028 ,  A61K31/7032 ,  C07H13/06 ,  C07H15/06 ,  A61P17/00 ,  A61P29/00 ,  A61P17/02

CPC classification number: A61K31/7032 ,  A61K9/0031 ,  A61K9/0053 ,  A61K35/741 ,  A61K2035/115 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06

Abstract: Provided herein are compositions comprising lipotechoic acid (LTA) and methods of use thereof for immune modulation. In particular, compositions comprising S. epidermidis lipotechoic Acid (SELTA) are provided, as well as method of use thereof for the treatment of immune- (e.g., autoimmune) and inflammation-related conditions and diseases (e.g., chronic pelvic pain syndrome (CPPS), arthritis, etc.).

公开(公告)号：WO2018153904A1

公开(公告)日：2018-08-30

申请号：PCT/EP2018/054258

申请日：2018-02-21

Applicant: MONTERO GIDA SANAYI VE TICARET A.S.

Inventor： TÜRKYILMAZ, Ali ,  PEHLIVAN AKALIN, Nur ,  KARACA, Gizem

IPC: A61K31/381 ,  A61K31/4415 ,  A61K31/51 ,  A61K31/714 ,  A61K47/02 ,  A61K47/22 ,  A61K47/24 ,  A61K47/36 ,  A61K47/38 ,  A61K9/00 ,  A61K9/20

CPC classification number: A61K31/714 ,  A61K9/0053 ,  A61K9/209 ,  A61K9/2095 ,  A61K9/2866 ,  A61K31/385 ,  A61K31/4415 ,  A61K31/51 ,  A61K47/38 ,  A61K2300/00

Abstract: The present invention relates to pharmaceutical compositions comprising alpha lipoic acid or a pharmaceutically acceptable salt thereof in combination with at least one water- soluble vitamin or pharmaceutically acceptable salts thereof.

公开(公告)号：WO2018129061A1

公开(公告)日：2018-07-12

申请号：PCT/US2018/012211

申请日：2018-01-03

Applicant: CORMEDIX INC.

Inventor： DILUCCIO, Robert

IPC: A61K31/549 ,  A61K9/00 ,  A61K9/107

CPC classification number: A61K31/549 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/0065 ,  A61K9/06 ,  A61K9/2077 ,  A61K9/4866 ,  A61K9/5015 ,  A61K9/5073 ,  A61K31/541 ,  A61P1/00 ,  C07D285/18

Abstract: This invention relates to the prophylactic and/or therapeutic application of antimicrobials that are, for example, administered orally as a delayed release formulation designed to release the drug to the distal small intestine and/or colon in high quantities and density, as a method for the prevention and/or treatment of infections in the colon.